Collaborative clinical research between EU & sub-Saharan Africa

European & Developing Countries Clinical Trials Partnership

Dr Monique Surette, EDCTP Senior Project Officer



EDCTP

European & Developing Countries Clinical Trials Partnership



Supported by the EU

EC Open Info Day - Horizon 2020 'Health, demographic change and wellbeing', Brussels (BE), 8 December 2017

EDCTP public-public partnership

14 European countries

Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden and United Kingdom

2 Aspirant members

Angola, Switzerland

16 African countries

Burkina Faso, Cameroon, Rep of Congo, Ethiopia, Gabon, Ghana, Mali, Mozambique, Niger, Nigeria, Senegal, South Africa, Tanzania, The Gambia, Uganda, Zambia



Vision

Reduce the individual, social and economic burden of poverty-related infectious diseases in sub-Saharan Africa, by investing in **collaborative clinical research** to develop accessible, suitable and affordable medical interventions and investing in **research capacity development**

Mission

To enhance research capacity and accelerate the development of new or improved medical interventions for the identification, treatment and prevention of **poverty-related infectious diseases**, including emerging and re-emerging diseases in sub-Saharan Africa, through all phases of **clinical trials, with emphasis on phase II and III trials**.

EDCTP timeline



*Independent evaluations commissioned by the EC.

The EDCTP funding programme



• Application of Participating States' funding

• Horizon 2020 rules for participation

EDCTP Programme objectives



Medical interventions

New or improved medical interventions against poverty-related infectious diseases



Collaboration and capacity development

Improve cooperation with sub-Saharan Africa through capacity building for conducting clinical trials according to ethical principles and regulatory standards



European coordination

Improve coordination, alignment and integration of European National Programmes



External partnerships

Increase international cooperation with public and private partners



EU cooperation

Increase interaction with other EU initiatives, including those linked to development assistance



- HIV, tuberculosis, malaria
- Neglected infectious diseases*

Dengue/severe dengue; rabies; human African trypanosomiasis (sleeping sickness); leishmaniases; cysticercosis/taeniasis; dracunculiasis (guinea-worm disease); echinococcosis; foodborne trematodiases; lymphatic filariasis; mycetoma; onchocerciasis (river blindness); schistosomiasis; soil-transmitted helminthiases; Buruli ulcer; leprosy (Hansen's disease); trachoma; yaws

- Diarrhoeal diseases
- Lower respiratory tract infections
- **Emerging and re-emerging infectious diseases** of particular relevance for Africa, such as Ebola virus disease and yellow fever.

^{*} Based on the WHO list of neglected tropical diseases (excluding Chagas disease)

Vulnerable populations



- Pregnant women
- Newborns and children
- Adolescents
- People living with coinfections and co-morbidities

European Union R&D funding under Horizon 2020



EDCTP supported activities

Research & Innovation Actions (RIA) Coordination & Support Actions (CSA) Training & Mobility Actions (TMA)

Multicentre clinical trials that are conducted by research consortia involving both European and African research teams, with integrated capacity development and

networking elements.

Support of activities that strengthen the enabling environment for conducting clinical trials and clinical research, including ethical review and regulatory capacity. Fellowships that focus on the career development of individual researchers or research team members.

EDCTP2 funding commitments (2014-2016)*

Action	No. calls	No. grants funded	Total amount awarded (M)
Research and Innovation			
Actions (RIA)	7	34	€217.9
Training & Mobility Actions			
(TMA)	7	56	€12.2
Coordination & Support			
Actions (CSA)	6	32	€28.4
Total	20	122	€258.5

*as of November 2017

Research and Innovation Actions (2014-2016)



EDCTP2 programme so far (2014-2016)



www.EDCTP.org

EU and global context

EDCTP involvement in broader trends

- Open access
 - Publications & data (European open science cloud)
- Transparency
 - clinical trial registration (PACTR)
 - Reports & databases: World RePort (NIH/World Bank, TAG, G-Finder, etc.
- Alignment
 - Sustainable Development Goals
 - national, regional and global priorities
- Emergency preparedness against infectious diseases
 - "Research capacity development in support of the EVD response" (2014)
 - "Research and clinical management of patients in PRD epidemics in sub-Saharan Africa" (2016)
- Antimicrobial resistance (AMR)



Thank you! surette@edctp.org

The EDCTP programme is supported under Horizon 2020, the European Union's Framework Programme for Research and Innovation.



EDCTP2 calls for proposals

RIA Numbers of proposals (2014-2016 Calls)

Call	LoIs	Full proposals invited (%)	Full proposals submitted	Funded (% over FP submitted)	Funded (% over LoI submitted)
RIA – 2014 - Diagnostics	88	22 (25.0%)	21	6 (28.6%)	6 (6.8%)
RIA – 2015 - Treatment	125	42 (33.6%)	40	4 (10.0%)	4 (3.2%)
RIA – 2015 - Strategic	45	10 (22.2%)	10	3 (30.0%)	3 (6.7%)
RIA – 2016- Vaccines	46	17 (37.0%)	15	6 (40.0)	6 (13.0)
RIA – 2016 - Maternal and child health	42	10 (23.8%)	10	4 (40.0)	4 (9.5)
RIA – 2016 – PRD Epidemics	10	3 (30.0%)	3	2 (66.7)	2 (20.0)
RIA – 2016 – Strategic	23	9 (39.1%)	8	5 (62.5)	5 (21.7)
Total	379	113 (29.8%)	107	30 (39.7%)	30 (11.6%)

EDCTP2 calls for proposals

Portfolio by disease/topic

Торіс	Number of RIAs (% of total)	Number of TMAs (% of total)	Number of CSAs (% of total)	Number overall (% of total)
Malaria	3 (10.0)	6 (12.8)	2 (6.3)	11 (10.1)
HIV and HIV-associated infections	6 (20.0)	12 (25.5)	2 (6.3)	20 (18.3)
ТВ	9 (30.0)	9 (19.1)	2 (6.3)	19 (18.3)
HIV/TB	3 (10.0)	1 (2.1)	0	4 (3.7)
NIDs	5 (16.7)	7 (14.9)	0	12 (11.0)
Emerging diseases	3 (10.0)	1 (2.1)	6 (18.8)	10 (9.2)
Lower respiratory tract infections (LRTI)	1 (3.3)	1 (2.1)	0	2 (1.8)
Diarrhoeal diseases (DD)	0	2 (4.3)	0	2 (1.8)
Ethics and Regulatory	0	0	14 (43.8)	14 (12.8)
Networks	0	0	4 (12.5)	4 (3.7)
Capacity building and training	0	7 (14.9)	2 (6.3)	10 (8.3)
Other	0	1 (2.1)	0	1 (0.9)
Total	30 (100.0)	47 (100.0)	32 (100.0)	109 (100.0)



EDCTP priority-setting mechanisms



STRATEGIC BUSINESS PLAN

- Overall programme strategy
- Scope of programme
- Funding mechanisms
- High-level priorities



THREE-YEAR PLAN

- Short and medium term priorities
- Estimated budgets

ANNUAL WORKPLAN

- Planned calls for proposals
- Participating States' Initiated Activities (PSIAs)
- Detailed targets

ANNUAL STRATEGIC RESEARCH AGENDA

 Annually adjusted priorities taking into account EDCTP criteria for prioritisation

Clinical studies supported by EDCTP



EDCTP clinical research

Medical Interventions	Clinical research activities supported	Outcome
Drug	Human Pharmacology Therapeutic exploratory Therapeutic confirmatory	Clinical development progress leading to registration of new medicinal product, therapeutic regimen, indication,
Vaccine	Therapeutic use (Phase I to IV studies)	formulation Optimised product formulations for special
	Safety and efficacyOptimisation of interventions for	populations
	special population groups	Development of pharmacovigilance
Microbicide	 Active surveillance to gather product's safety data 	platforms and product registries
	F	New methodologies and appropriate medical devices for PRDs diagnosis
Diagnostics	Biomarkers	
5	Pharmacogenomics	Optimising the delivery of existing interventions
	Implementation research for test	
	validation	Guidelines on benefit of medical
Preventive or curative	 Pragmatic studies on effectiveness 	intervention in health care
	 Implementation research with a product focus 	Influencing disease management policies

Outcome from EDCTP research activities



- Clinical development progress leading to registration of new medicinal products, therapeutic regimens, indications
- Optimised product formulations for special populations
- Development of pharmacovigilance platforms and product registries
- New methodologies and appropriate medical devices for diagnosis of PRDs
- Optimising the delivery of existing interventions to contribute to a high level of public health
- Guidelines on benefit of medical interventions in health care
- Changing disease management policies

EDCTP strategy for capacity development



EDCTP Fellowship schemes



Objective: to support researchers and key members of clinical trial research teams from low- and middle-income countries to acquire specific skills in clinical trials research through placements in pharmaceutical companies, CROs, clinical or academic affiliated research organisations and PDPs.

Target individuals:

- Post-graduate (MSc or PhD) or medical graduate with clinical and/or research experience in infectious diseases
- Post-graduate or medical graduate degree within 15 years of submission of the application
- Researcher or clinical staff member employed for the last 12 months in an organisation with a registered legal entity in sub-Saharan Africa.

Funding level: 100% of eligible costs

Max. funding: €100,000

EDCTP-AREF PREPARATORY FELLOWSHIP

Objective: to enhance the competitiveness of up-and-coming post-doctoral African scientists and clinicians aspiring to win international/regional/national fellowships or grant support through short-term placements at a host organisation in EU Member States, in countries associated to Horizon 2020 or in sub-Saharan Africa which will be contracted by the home organisation to host the fellow.

Target individuals:

- Post-doctoral scientists
- Individuals who have been awarded their doctorate within three years before submission deadline
- PhD students or MDs who have been active researchers for up to three years following award of their doctorate
- Resident of, or willing to relocate to, a sub-Saharan African country

Funding level: 100% of eligible costs

Max. funding: €70,000

Joint call by EDCTP and the Africa Research Excellence Fund (AREF).

CAREER DEVELOPMENT FELLOWSHIP

Objective: to support junior to midcareer researchers to train and develop their clinical research skills. The objectives are to promote career development and retention of postdoctoral researchers and postgraduate medical researchers in the research field and in sub-Saharan Africa; and to equip the fellows with the ability to establish themselves as independent researchers and with the skills to initiate and manage their own research at host organisations in sub-Saharan Africa.

Target individuals:

- Resident of, or willing to relocate to, a sub-Saharan African country
- A graduate in a subject relevant to the EDCTP2 programme, with a PhD and up to five years' relevant postdoctoral research experience, or a medical doctor with up to five years' research experience
- At least one publication in an international peer-reviewed journal

Funding level: 100% of eligible costs

Max. funding: €150,000

SENIOR FELLOWSHIPS

Objective: to support capacity development of potential African research leaders using the train-thetrainer model and to mentor junior researchers with hands-on training linked to clinical trials activities in sub-Saharan Africa.

Target individuals:

- Resident of, or willing to relocate to, a sub-Saharan African country
- A graduate in a subject relevant to the EDCTP2 programme, with a PhD and a minimum of five years' relevant research experience after the doctorate, or a medical doctor with a post-graduate qualification in a subject relevant to the EDCTP2 programme, and a minimum of five years' research experience after the post-graduate qualification
- A minimum of 5 first-author publications in international peerreviewer journals

Funding level: 100% of eligible costs

Max. funding: €500,000.

Building international collaboration



Criteria for setting priorities

State of the product For each disease area, these analyses identify the current development state of clinical development of interventions for landscape treatment, prevention and diagnosis. 2 Analyses of disease burdens and changing patterns of **Priority infections** disease feed into priority setting for the poverty-related infectious diseases targeted by EDCTP. 3 **Disease burden and** These analyses identify key knowledge gaps and need for treatment/prevention new evidence. priorities Our expansion into new disease areas and into post-licensing **Emerging** studies, including effectiveness studies, pharmacovigilance and opportunities product-focused implementation research, provides new opportunities for EDCTP to achieve impact. 5 We aim to develop and sustain a balanced portfolio, across **Balanced** disease areas, types of intervention and type of study, portfolio balancing short-term and long-term priorities; this will help to ensure steady flows through product development pipelines.

Key features of EDCTP

We were established as a flagship European–African partnership and are recognised as an international funder of clinical research for povertyrelated infectious diseases. We are enhancing the research capacity of sub-Saharan African countries to conduct clinical studies in compliance with ethical and regulatory standards.

We operate as a true 'partnership of equals' between North and South, with input from African countries at all levels.

Key features of EDCTP

We support studies encompassing populations often excluded from clinical studies but with major unmet medical needs.



Our expansion to cover product-focused implementation research on delivery and uptake of medical research outputs makes our work more relevant to health services in sub-Saharan Africa. It also provides new opportunities for partnership with development assistance initiatives.

Key features of EDCTP

We focus on clinical challenges and policyrelevant questions, ensuring results of funded research feed directly into national and international policy-making. We are committed to working with like-minded partners to promote wider use of the opportunities established for collaborative research.

EDCTP supported activities

Research & Innovation	Coordination & Support	Training & Mobility
Actions (RIA)	Actions (CSA)	Actions (TMA)
Multicentre clinical trials that are conducted by research consortia involving both European and African research teams, with integrated capacity development and	Support of activities that strengthen the enabling environment for conducting clinical trials and clinical research, including ethical review and regulatory capacity.	Fellowships that focus on the career development of individual researchers or research team members.

networking elements.

Eligibility criteria for EDCTP calls for proposals

Research & Innovation Actions (RIA)	Coordination & Support Actions (CSA)	Training & Mobility Actions (TMA)
Consortia of \ge 2 European countries and \ge 1 sub- Saharan African country	Individual institutions or consortia for ethics, training, networking and regulatory activities	Grants to individuals: Career development, Senior, other
Either full funding (RIA) (100% of costs) or cofunding (SRIA) (≤50%) with other funders (PSs and/or third parties)	100% funding	100% funding
Broad non-prescriptive topics, bottom-up		

Competitive process for grants

Annual work plan with call topics



Types of co-funding by EDCTP Participating States



What are the Participating States' Initiated Activities (PSIAs)

Activities funded and managed by a single or several Participating States (independently or jointly) that fall within the scope of the EDCTP programme, based on common principles.

Equal treatment

Transparency

Independent peer review evaluation

Ethics and scientific integrity

Functional appeal system

Exploitation and dissemination of results

What are eligible PSIAs?

Activities within the EDCTP scope

